CAMP · Camp4 Therapeutics Corp · Executive Compensation
$3.84
-0.20 (-4.95%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$245.37M
Shares
62.75M
Volume · Oct 1
994.72K
Avg daily vol (3M)
254.33K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Josh Mandel-Brehm | Chief Executive Officer | $3,327,238 |
| Kelly Gold | Chief Financial Officer | $1,846,733 |
| Yuri Maricich | Chief Medical Officer | $1,814,042 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Yuri Maricich | Chief Medical Officer | $2,521,505 |
| Josh Mandel-Brehm | Chief Executive Officer | $2,294,985 |
| Kelly Gold | Chief Financial Officer | $1,310,523 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Josh Mandel-Brehm | Chief Executive Officer | $696,281 |
| Kelly Gold | Chief Financial Officer | $628,834 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Michael MacLean | Class III director | Appointed | 2026-03-24 |
| Daniel Tardiff | Chief Scientific Officer | Appointed | 2025-09-10 |
| Doug Williams | Board Chair | Appointed | 2025-09-10 |
| Ravi Thadhani | Board of Directors | Resigned | 2025-09-10 |
| Paula Ragan | Board of Directors | Resigned | 2025-09-10 |
| James Boylan | Board of Directors | Resigned | 2025-09-10 |
| Daniel Tardiff, PhD | Chief Scientific Officer | Appointed | 2025-09-10 |
| Paula Ragan, Ph.D. | member of the Board | Resigned | 2025-09-10 |
| Ravi Thadhani, M.D. | member of the Board | Resigned | 2025-09-10 |
| James Boylan | member of the Board | Resigned | 2025-09-10 |
| Murray Stewart, DM FRCP | Class II director | Appointed | 2025-03-18 |
| Douglas Williams, PhD | Class I director | Appointed | 2025-03-18 |